Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17114462 | 0.98 | CA12 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17317414 | 0.87 | TSHR (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28295322 | 0.86 | CA12 (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL27861005 | 0.81 | CA12 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL19849257 | 0.81 | CA12 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29819654 | 0.81 | NPC1 (0.66) | SMN1; SMN2NPC1CTSDKMT2A | |
| SCHEMBL20239567 | 0.81 | NPC1 (0.66) | SMN1; SMN2NPC1CTSDKMT2A | |
| SCHEMBL28035202 | 0.80 | FEN1 (0.43) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17114470 | 0.79 | NPC1 (0.64) | SMN1; SMN2NPC1CTSDKMT2A | |
| SCHEMBL17114471 | 0.79 | NPC1 (0.64) | SMN1; SMN2NPC1CTSDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026739-A1 | COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2025-01-23 | — | — | US | disclosed |
| EP-4479040-A1 | COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF | Full-Life Technologies HK Limited (HK) | 2024-12-25 | — | — | EP | disclosed |
| CN-119136796-A | Neurotensin receptor-targeting compounds and radioligands and uses thereof | 辐联科技香港有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-12145926-B2 | Compounds and radioligands for targeting neurotensin receptor and uses thereof | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2024-11-19 | — | — | US | disclosed |
| US-20240287046-A1 | COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2024-08-29 | — | — | US | disclosed |
| WO-2023158802-A1 | COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF | FULL-LIFE TECHNOLOGIES U.S. INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023158802-A1 | COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF | FULL-LIFE TECHNOLOGIES U.S. INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| CN-109790152-B | Diagnosis, treatment and prevention of neurotensin receptor-related disorders | 埃朗根-纽伦堡 弗里德里希-亚历山大大学 | 2022-05-24 | — | — | CN | disclosed |
| US-11180511-B2 | Diagnosis, treatment and prevention of neurotensin receptor-related conditions | FRIEDRICH-ALEXANDER-UNIVERSITÄT ERLANGEN-NÜRNBERG; UNIVERSITÄTSKLINIKUM ERLANGEN (DE) | 2021-11-23 | — | — | US | disclosed |
| EP-3494114-B1 | DIAGNOSIS, TREATMENT AND PREVENTION OF NEUROTENSIN RECEPTOR-RELATED CONDITIONS | UNIV FRIEDRICH ALEXANDER ER (DE) | 2020-12-23 | — | — | EP | disclosed |
| EP-3494114-B1 | DIAGNOSIS, TREATMENT AND PREVENTION OF NEUROTENSIN RECEPTOR-RELATED CONDITIONS | UNIV FRIEDRICH ALEXANDER ER (DE) | 2020-12-23 | — | — | EP | disclosed |
| US-20200377523-A1 | DIAGNOSIS, TREATMENT AND PREVENTION OF NEUROTENSIN RECEPTOR-RELATED CONDITIONS | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2020-12-03 | — | — | US | disclosed |
| EP-3494114-A1 | DIAGNOSIS, TREATMENT AND PREVENTION OF NEUROTENSIN RECEPTOR-RELATED CONDITIONS | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2019-06-12 | — | — | EP | disclosed |
| WO-2018024789-A1 | DIAGNOSIS, TREATMENT AND PREVENTION OF NEUROTENSIN RECEPTOR-RELATED CONDITIONS | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2018-02-08 | — | — | WO | disclosed |
| EP-3279197-A1 | DIAGNOSIS, TREATMENT AND PREVENTION OF NEUROTENSIN RECEPTOR-RELATED CONDITIONS | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2018-02-07 | — | — | EP | disclosed |
| WO-2011156557-A2 | COMPOUNDS ACTIVE AT THE NEUROTENSIN RECEPTOR | THOMAS JAMES B (US) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026739-A1 | COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF | NTSR1, NTSR2, NPSR1 | CA12 300/4885CA1 651/4885CA2 820/4885 |
| US-20240287046-A1 | COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF | NTSR1, NTSR2, NPSR1 | CA12 247/4885CA1 545/4885CA2 821/4885 |
| US-11180511-B2 | Diagnosis, treatment and prevention of neurotensin receptor-related conditions | NTSR1, NTSR2, NPSR1 | CA12 280/4885CA1 1342/4885CA2 973/4885 |
| US-12145926-B2 | Compounds and radioligands for targeting neurotensin receptor and uses thereof | NTSR1, NTSR2, NPSR1 | CA12 247/4885CA1 545/4885CA2 821/4885 |
| US-20200377523-A1 | DIAGNOSIS, TREATMENT AND PREVENTION OF NEUROTENSIN RECEPTOR-RELATED CONDITIONS | NTSR1, NTSR2, NPSR1 | CA12 280/4885CA1 1342/4885CA2 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.